Tag: Nicox
Nicox: Half-year report on the liquidity contract with Kepler Cheuvreux (as of June 30, 2023) – 07/11/2023 at 07:48
Under the liquidity contract entrusted by Nicox to Kepler Cheuvreux, on June 30, 2023, the following resources appeared in the liquidity account:• 304,567 titles• €10,640.56 in cash • Number of…
Nicox up sharply after study on NCX 470 trade outlook – 7/10/2023 at 10:03 am
(AOF) – Nicox (+ 14.69% to 0.53 euro) posted one of the strongest increases in the SRD market after having made public a market study according to which its product…
Nicox: surrounded after a market study – 07/10/2023 at 10:47
(CercleFinance.com) – Nicox jumped 11% after its announcement that annual worldwide net sales of the NCX 470 could potentially reach at least $300 million within eight years of commercial launches…
Nicox: Presentation at the World Glaucoma Congress of Data on NCX 470 from the Adaptive Dose Selection Step of the Phase 3 Mont Blanc Study and Analysis of Patient Subgroups Showing Superiority of NCX 470 compared to latanoprost – 07/03/2023 at 07:41
Nicox announced that additional data on NCX 470 was presented at the 10th World Glaucoma Congress (WGC) held from June 28 to July 1, 2023 in Rome, Italy. NCX 470…
For Kepler Cheuvreux, the experimental treatment of Nicox against glaucoma “must improve its efficacy profile”
Posted Jan 10, 2023, 3:32 PMUpdated Jan 10, 2023, 3:34 PM Nicox has been kept out of the rebound in biotechnology stocks since the start of the year. Today, the…
Nicox: the title flies away, progress on Zerviate in China – 04/14/2023 at 10:55
(CercleFinance.com) – Nicox stock soared on the Paris Stock Exchange this Friday after the ophthalmology company announced that its Chinese partner had submitted a marketing authorization request in China. At…
Nicox: request for authorization of Zerviate in China for 2024 – 04/14/2023 at 11:08
(AOF) – Nicox, today announced that its Chinese exclusive licensee partner, Ocumension Therapeutics, has submitted a marketing authorization application in China for Zerviate (cetirizine ophthalmic solution), 0.24% for the eye…
Nicox publishes a cash position of 27.7 million euros at the end of December 2022 – 03/20/2023 at 15:05
(AOF) – Nicox, an international company specializing in ophthalmology, announces cash as of December 31, 2022 of 27.7 million euros against 42.0 million at the end of 2021, and estimates…
Nicox: losses reduced in 2022, but cash flow down
(CercleFinance.com) – Nicox reduced its losses last year, but also saw its turnover and its cash dwindle, a trend which weighed on the share price of the pharmaceutical company Monday…
Nicox: HBM Healthcare Investments drops below 5% – 01/23/2023 at 10:45 am
(CercleFinance.com) – HBM Healthcare Investments (Cayman) Ltd declared to the AMF that it crossed downwards, on January 18, the thresholds of 5% of the capital and voting rights of Nicox…
Nicox: HBM Healthcare Investments drops below 5%
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Nicox: towards a transfer to Euronext Growth – 01/09/2023 at 11:58
(CercleFinance.com) – The Nicox ophthalmology laboratory announces its intention to transfer the listing of its shares from the regulated Euronext Paris market to Euronext Growth Paris and, to this end,…